Novartis' heart failure drug misses expanded use trial targe...

Novartis has announced that its heart failure drug Entresto has failed in a trial that the company hoped would extend its use to a new group of patients with preserved ejection fraction.

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failu...

Novartis' canakinumab cuts risk for heart attack survivors

Novartis to discuss canakinumab results with regulators.

Blow for Novartis as heart failure drug flops

Could this be the end of the road for serelaxin?

MSD and Bayer launch big gamble on heart failure candidate

Aims to recruit 4,900 patients to prove value in heart failure

Medtronic to buy HeartWare, expand heart failure portfolio

Deal worth an estimated $1.1 billion.